{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T12:37:10Z","timestamp":1773923830595,"version":"3.50.1"},"reference-count":100,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2014,3,1]],"date-time":"2014-03-01T00:00:00Z","timestamp":1393632000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2014,3]]},"DOI":"10.1007\/s40265-014-0194-8","type":"journal-article","created":{"date-parts":[[2014,3,6]],"date-time":"2014-03-06T12:20:17Z","timestamp":1394108417000},"page":"465-488","source":"Crossref","is-referenced-by-count":39,"title":["QVA149 (Indacaterol\/Glycopyrronium Fixed-Dose Combination): A Review of Its Use in Patients with Chronic Obstructive Pulmonary Disease"],"prefix":"10.1007","volume":"74","author":[{"given":"James E.","family":"Frampton","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,3,7]]},"reference":[{"issue":"4","key":"194_CR1","doi-asserted-by":"crossref","first-page":"543","DOI":"10.2165\/11208490-000000000-00000","volume":"72","author":"K McKeage","year":"2012","unstructured":"McKeage K. Indacaterol: a review of its use as maintenance therapy in patients with chronic obstructive pulmonary disease. Drugs. 2012;72(4):543\u201363.","journal-title":"Drugs."},{"issue":"7","key":"194_CR2","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1007\/s40265-013-0058-7","volume":"73","author":"NJ Carter","year":"2013","unstructured":"Carter NJ. Inhaled glycopyrronium bromide: a review of its use in patients with moderate to severe chronic obstructive pulmonary disease. Drugs. 2013;73(7):741\u201353.","journal-title":"Drugs."},{"key":"194_CR3","unstructured":"Novartis. Novartis first-in-class once-daily dual bronchodilator Ultibro Breezhaler (QVA149) achieves near simultaneous approval for COPD patients in Europe and Japan [media release]. 23 Sep 2013. http:\/\/www.novartis.com\/newsroom\/media-releases\/en\/2013\/1730580.shtml ."},{"key":"194_CR4","unstructured":"Novartis Pharma K.K. Ultibro inhalation capsules: Japanese prescribing information. 2013. http:\/\/product.novartis.co.jp\/ult\/pi\/ULT1309_03.pdf . Accessed 31 Jan 2014."},{"key":"194_CR5","unstructured":"Novartis Europharm Ltd. Ultibro Breezhaler 85 micrograms\/43 micrograms, inhalation powder hard capsules: EU summary of product characteristics. 2013. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002679\/WC500151255.pdf . Accessed 13 Nov 2013."},{"key":"194_CR6","doi-asserted-by":"crossref","first-page":"501","DOI":"10.2147\/COPD.S49615","volume":"8","author":"R Dahl","year":"2013","unstructured":"Dahl R, Dalal J, Alagappan VKT, et al. Efficacy and safety of QVA149 compared to the concurrent administration of its monocomponents indacaterol and glycopyrronium: the BEACON study. Int J COPD. 2013;8:501\u20138.","journal-title":"Int J COPD."},{"issue":"2","key":"194_CR7","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1164\/rccm.200910-1500OC","volume":"182","author":"JF Donohue","year":"2010","unstructured":"Donohue JF, Fogarty C, L\u00f6tvall J, et al. Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. Am J Respir Crit Care Med. 2010;182(2):155\u201362.","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"194_CR8","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1136\/thx.2009.125435","volume":"65","author":"R Dahl","year":"2010","unstructured":"Dahl R, Chung KF, Buhl R, et al. Efficacy of a new once-daily long-acting inhaled \u03b22-agonist indacaterol versus twice-daily formoterol in COPD. Thorax. 2010;65(6):473\u20139.","journal-title":"Thorax"},{"key":"194_CR9","author":"G Feldman","year":"2010","unstructured":"Feldman G, Siler T, Prasad N, et al. Efficacy and safety of indacaterol 150\u00a0\u03bcg once-daily in COPD: a double-blind, randomized, 12-week study. BMC Pulm Med. 2010. doi: 10.1186\/1471-2466-10-11 .","journal-title":"BMC Pulm Med"},{"issue":"2","key":"194_CR10","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1183\/09031936.00045810","volume":"37","author":"O Kornmann","year":"2011","unstructured":"Kornmann O, Dahl R, Centanni S, et al. Once-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparison. Eur Respir J. 2011;37(2):273\u20139.","journal-title":"Eur Respir J"},{"issue":"5","key":"194_CR11","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.rmed.2011.02.008","volume":"105","author":"S Korn","year":"2011","unstructured":"Korn S, Kerwin E, Atis S, et al. Indacaterol once daily provides superior efficacy to salmeterol twice daily in COPD: a 12-week study. Respir Med. 2011;105(5):719\u201326.","journal-title":"Respir Med"},{"issue":"4","key":"194_CR12","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1183\/09031936.00191810","volume":"38","author":"R Buhl","year":"2011","unstructured":"Buhl R, Dunn LJ, Disdier C, et al. Blinded 12-week comparison of once-daily indacaterol and tiotropium in COPD. Eur Respir J. 2011;38(4):797\u2013803.","journal-title":"Eur Respir J"},{"key":"194_CR13","doi-asserted-by":"crossref","unstructured":"DeCramer ML, Chapman KR, Dahl R, et al. Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group study. Lancet Respir Med. 2013;1(7):524\u201333.","DOI":"10.1016\/S2213-2600(13)70158-9"},{"issue":"1","key":"194_CR14","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1378\/chest.10-1830","volume":"140","author":"KR Chapman","year":"2011","unstructured":"Chapman KR, Rennard SI, Dogra A, et al. Long-term safety and efficacy of indacaterol, a long-acting \u03b22-agonist, in subjects with COPD: a randomized, placebo-controlled study. Chest. 2011;140(1):68\u201375.","journal-title":"Chest"},{"issue":"2","key":"194_CR15","doi-asserted-by":"crossref","first-page":"153","DOI":"10.5414\/CPP49153","volume":"49","author":"S Pascoe","year":"2011","unstructured":"Pascoe S, Reynolds C, Pleskow W, et al. Safety, tolerability and pharmacokinetics of single escalating doses of indacaterol, a once-daily beta2-agonist bronchodilator, in subjects with COPD. Int J Clin Pharmacol Ther. 2011;49(2):153\u201361.","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"2","key":"194_CR16","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1124\/jpet.112.194456","volume":"343","author":"DA Sykes","year":"2012","unstructured":"Sykes DA, Dowling MR, Leighton-Davies J, et al. The influence of receptor kinetics on the onset and duration of action and the therapeutic index of NVA237 and tiotropium. J Pharmacol Exp Ther. 2012;343(2):520\u20138.","journal-title":"J Pharmacol Exp Ther"},{"key":"194_CR17","author":"A D\u2019Urzo","year":"2011","unstructured":"D\u2019Urzo A, Ferguson GT, van Noord JA, et al. Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trial. Respir Res. 2011. doi: 10.1186\/1465-9921-12-156 .","journal-title":"Respir Res"},{"issue":"5","key":"194_CR18","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1183\/09031936.00040712","volume":"40","author":"E Kerwin","year":"2012","unstructured":"Kerwin E, H\u00e9bert J, Gallagher N, et al. Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study. Eur Respir J. 2012;40(5):1106\u201314.","journal-title":"Eur Respir J"},{"key":"194_CR19","unstructured":"Drollmann A, Brown M, Sechaud R, et al. Effect of once-daily QVA149 on cardiac safety in healthy volunteers [abstract no. F64]. American Thoracic Society 109th international conference; 17\u201322 May 2013; Philadelphia (PA)."},{"issue":"6","key":"194_CR20","doi-asserted-by":"crossref","first-page":"418","DOI":"10.3109\/15412555.2010.528812","volume":"7","author":"B Maele Van de","year":"2010","unstructured":"Van de Maele B, Fabbri LM, Martin C, et al. Cardiovascular safety of QVA149, a combination of indacaterol and NVA237. COPD patients. COPD. 2010;7(6):418\u201327.","journal-title":"COPD"},{"issue":"1","key":"194_CR21","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1517\/17425255.2014.865723","volume":"10","author":"M Cazzola","year":"2014","unstructured":"Cazzola M, Calzetta L, Page CP, et al. Use of indacaterol for the treatment of COPD: a pharmacokinetic evaluation. Expert Opin Drug Metab Toxicol. 2014;10(1):129\u201337.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"194_CR22","unstructured":"European Medicines Agency, Committee for Medicinal Products for Human Use (CHMP). CHMP assessment report: Ultibro Breezhaler. International non-proprietary names: indacaterol \/glycopyrronium bromide. 2013. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Public_assessment_report\/human\/002679\/WC500151257.pdf . Accessed 14 Nov 2013."},{"key":"194_CR23","unstructured":"Asai K, Minakata Y, Hirata K, et al. Once-daily QVA149 is safe and well tolerated and improves lung function and health status in Japanese patients with COPD: the ARISE study [poster]. European Respiratory Society 23rd Annual Congress; 7\u201311 Sep 2013; Barcelona."},{"key":"194_CR24","unstructured":"Novartis Pharmaceuticals. Long term safety and tolerability of QVA149 versus tiotropium in Japanese patients with chronic obstructive pulmonary disease (COPD) (ARISE) [ClinicalTrials.gov identifier NCT01285492]. US National Institutes of Health, ClinicalTrials.gov [online]. 2013. http:\/\/clinicaltrials.gov\/show\/NCT01285492 . Accessed 9 Oct 2013."},{"key":"194_CR25","doi-asserted-by":"crossref","unstructured":"Mahler DA, Decramer M, D\u2019Urzo A, et al. Dual bronchodilation with QVA149 reduces patient-reported dyspnoea in COPD: BLAZE study. Eur Respir J. 2013. doi: 10.1183\/09031936.00124013 .","DOI":"10.1183\/09031936.00124013"},{"key":"194_CR26","unstructured":"Mahler DA, Decramer M, D\u2019Urzo AD, et al. Superior lung function with once-daily QVA149 translates into improvements in patient-reported breathlessness compared with placebo and tiotropium In COPD patients: the BLAZE study [abstract P236 plus oral presentation]. American Thoracic Society 109th international conference; 17\u201322 May 2013; Philadelphia (PA)."},{"key":"194_CR27","author":"KM Beeh","year":"2014","unstructured":"Beeh KM, Korn S, Beier J, et al. Effect of QVA149 on lung volumes and exercise tolerance in COPD patients: the BRIGHT study. Respir Med. 2014. doi: 10.1016\/j.rmed.2014.01.006 .","journal-title":"Respir Med"},{"key":"194_CR28","unstructured":"Novartis Pharmaceuticals. Effect of QVA149 on exercise tolerance in patients with chronic obstructive pulmonary disease (COPD) (BRIGHT) [ClinicalTrials.gov identifier NCT01294787]. US National Institutes of Health, ClinicalTrials.gov [online]. 2013. http:\/\/clinicaltrials.gov\/show\/NCT01294787 . Accessed 9 Oct 2013."},{"issue":"10","key":"194_CR29","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1016\/j.rmed.2013.05.016","volume":"107","author":"R Dahl","year":"2013","unstructured":"Dahl R, Chapman KR, Rudolf M, et al. Safety and efficacy of dual bronchodilation with QVA149 in COPD patients: the ENLIGHTEN study. Respir Med. 2013;107(10):1558\u201367.","journal-title":"Respir Med"},{"key":"194_CR30","unstructured":"Banerji D, Alagappan V, Green Y, et al. Dual bronchodilation with once-daily QVA149 improves dyspnoea and health status and reduces symptoms and rescue medication use in patients with COPD: the IGNITE trials [poster]. European Respiratory Society 23rd Annual Congress; 7\u201311 Sep 2013; Barcelona."},{"key":"194_CR31","unstructured":"Novartis Pharmaceuticals. A 52-week treatment, multi-center, randomized, double-blind, double dummy, parallel-group, active controlled study to compare the effect of QVA149 (indacaterol maleate\/glycopyrronium bromide) with salmeterol\/fluticasone on the rate of exacerbations in subjects with moderate to very severe COPD (FLAME) [ClinicalTrials.gov identifier NCT01782326]. US National Institutes of Health, ClinicalTrials.gov [online]. 2013. http:\/\/clinicaltrials.gov\/show\/NCT01782326 . Accessed 9 Oct 2013."},{"issue":"1","key":"194_CR32","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S2213-2600(12)70052-8","volume":"1","author":"CF Vogelmeier","year":"2013","unstructured":"Vogelmeier CF, Bateman ED, Pallante J, et al. Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study. Lancet Respir Med. 2013;1(1):51\u201360.","journal-title":"Lancet Respir Med"},{"key":"194_CR33","unstructured":"Bateman ED, Vogelmeier C, Pallante J, et al. Once-daily QVA149 improves breathlessness and reduces rescue medication use compared to twice-daily salmeterol\/fluticasone in patients with COPD: the ILLUMINATE study [abstract no. 807]. American Thoracic Society 109th international conference; 17\u201322 May 2013; Philadelphia (PA)."},{"key":"194_CR34","unstructured":"Dahl R, Gallagher N, Green Y, et al. QVA149 provides a rapid onset of action which is sustained throughout treatment in patients with COPD [poster]. European Respiratory Society 23rd Annual Congress; 7\u201311 Sep 2013; Barcelona."},{"key":"194_CR35","unstructured":"Vogelmeier C, Dahl R, D\u2019Urzo A, et al. Once-daily QVA149 provides clinically meaningful improvements in lung function and clinical outcomes [poster]. European Respiratory Society 23rd Annual Congress; 7\u201311 Sep 2013; Barcelona."},{"key":"194_CR36","unstructured":"Barnes N, Hashimoto S, Nagase T, et al. QVA149 provides superior peak lung function in patients with COPD [poster]. European Respiratory Society 23rd Annual Congress; 7\u201311 Sep 2013; Barcelona."},{"key":"194_CR37","unstructured":"Gallagher N, Alagappan V, Green Y, et al. Dual bronchodilation with once-daily QVA149 improves lung function and reduces exacerbations in patients with COPD: the IGNITE trials [poster]. European Respiratory Society 23rd Annual Congress; 7\u201311 Sep 2013; Barcelona."},{"key":"194_CR38","unstructured":"Welte T, Dahl R, Chen H, et al. Once-daily QVA149 improves symptom scores in patients with COPD [poster]. European Respiratory Society 23rd Annual Congress; 7\u201311 Sep 2013; Barcelona."},{"key":"194_CR39","unstructured":"Novartis Pharmaceuticals. A 26-week treatment randomized, double-blind, double dummy, parallel-group study to assess the efficacy, safety and tolerability of QVA149 (indacaterol\/glycopyrronium bromide) compared to fluticasone\/salmeterol in patients with moderate to severe chronic obstructive pulmonary disease [ClinicalTrials.gov identifier NCT01709903]. US National Institutes of Health, ClinicalTrials.gov [online]. 2013. http:\/\/clinicaltrials.gov\/show\/NCT01709903 . Accessed 9 Oct 2013."},{"key":"194_CR40","unstructured":"Novartis Pharmaceuticals. Comparison of long-term safety of the combination product QVA149A against placebo and standard of care treatment in chronic obstructive pulmonary disease patients with moderate to severe airflow limitation (RADIATE) [ClinicalTrials.gov identifier NCT01610037]. US National Institutes of Health, ClinicalTrials.gov [online]. 2013. http:\/\/clinicaltrials.gov\/show\/NCT01610037 . Accessed 9 Oct 2013."},{"key":"194_CR41","doi-asserted-by":"crossref","unstructured":"Bateman ED, Ferguson GT, Barnes N, et al. Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study. Eur Respir J. 2013;42(6):1484\u201394.","DOI":"10.1183\/09031936.00200212"},{"key":"194_CR42","unstructured":"Welte T, Gallagher N, Green Y, et al. Dual bronchodilation with once-daily QVA149 provides significantly improved clinical outcomes versus mono-bronchodilator therapy: the SHINE study [abstract no. G25]. American Thoracic Society 109th international conference; 17\u201322 May 2013; Philadelphia (PA)."},{"key":"194_CR43","unstructured":"Bateman ED, Ferguson GT, Welte T, et al. Dual bronchodilation with once-daily QVA149 significantly improves lung function versus single bronchodilators and salmeterol\/fluticasone [abstract no. G30]. American Thoracic Society 109th international conference; 17\u201322 May 2013; Philadelphia (PA)."},{"issue":"3","key":"194_CR44","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S2213-2600(13)70052-3","volume":"1","author":"JA Wedzicha","year":"2013","unstructured":"Wedzicha JA, Decramer M, Ficker JH, et al. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study. Lancet Respir Med. 2013;1(3):199\u2013209.","journal-title":"Lancet Respir Med"},{"key":"194_CR45","doi-asserted-by":"crossref","unstructured":"Ficker J, Wedzicha JA, Decramer M, et al. QVA149 improves lung function and reduces exacerbations compared to tiotropium in patients with severe-to-very severe COPD: the SPARK study [poster]. European Respiratory Society 23rd Annual Congress; 7\u201311 Sep 2013; Barcelona.","DOI":"10.1378\/chest.1824301"},{"key":"194_CR46","unstructured":"Banerji D, Fowler Taylor A, Kho P, et al. Once-daily QVA149 provides superior improvements in lung function compared with glycopyrronium and tiotropium in severe COPD patients: a 52\u00a0week pooled analysis [poster]. European Respiratory Society 23rd Annual Congress; 7\u201311 Sep 2013; Barcelona."},{"key":"194_CR47","doi-asserted-by":"crossref","unstructured":"Wedzicha JA, Decramer M, Vestbo J, et al. A novel study design for the comparison between once-daily QVA149 and twice-daily salmeterol\/fluticasone on the reduction of COPD exacerbations: the FLAME study [poster]. European Respiratory Society 23rd Annual Congress; 7\u201311 Sep 2013; Barcelona.","DOI":"10.1378\/chest.1824340"},{"key":"194_CR48","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1081\/COPD-200053377","volume":"2","author":"JF Donohue","year":"2005","unstructured":"Donohue JF. Minimal clinically important differences in COPD lung function. COPD. 2005;2:111\u201324.","journal-title":"COPD"},{"issue":"2","key":"194_CR49","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1183\/09031936.00099306","volume":"31","author":"M Cazzola","year":"2008","unstructured":"Cazzola M, MacNee W, Martinez FJ, et al. Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J. 2008;31(2):416\u201369.","journal-title":"Eur Respir J"},{"issue":"3","key":"194_CR50","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1164\/rccm.201310-1863PP","volume":"189","author":"PW Jones","year":"2014","unstructured":"Jones PW, Beeh KM, Chapman KR, et al. Minimal clinically important differences in pharmacological trials. Am J Respir Crit Care Med. 2014;189(3):250\u20135.","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"194_CR51","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1081\/COPD-200050666","volume":"2","author":"DA Mahler","year":"2005","unstructured":"Mahler DA, Witek TJ Jr. The MCID of the transition dyspnea index is a total score of one unit. COPD. 2005;2(1):99\u2013103.","journal-title":"COPD"},{"issue":"1","key":"194_CR52","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1081\/COPD-200050513","volume":"2","author":"PW Jones","year":"2005","unstructured":"Jones PW. St George\u2019s Respiratory Questionnaire: MCID. COPD. 2005;2(1):75\u20139.","journal-title":"COPD"},{"key":"194_CR53","unstructured":"Welte T, Vogelmeier C, Dahl R, et al. Once-daily QVA149 has a good safety profile in patients with COPD [poster]. European Respiratory Society 23rd Annual Congress; 7\u201311 Sep 2013; Barcelona."},{"key":"194_CR54","unstructured":"Ferguson GT, Barnes N, Mehta R, et al. Cardio- and cerebro-vascular safety of QVA149: results from a pooled analysis [poster]. European Respiratory Society 23rd Annual Congress; 7\u201311 Sep 2013; Barcelona."},{"key":"194_CR55","unstructured":"Chen H, D\u2019Andrea P, Banerji D. QVA149 does not increase the risk of cardio- and cerebro-vascular events, pneumonia and exacerbation events compared with placebo: a network meta-analysis across multiple safety databases [poster]. European Respiratory Society 23rd Annual Congress; 7\u201311 Sep 2013; Barcelona."},{"key":"194_CR56","unstructured":"Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease (updated 2014). http:\/\/www.goldcopd.org\/ . Accessed 30 Jan 2014."},{"key":"194_CR57","first-page":"153","volume":"5","author":"ES Gladysheva","year":"2010","unstructured":"Gladysheva ES, Malhotra A, Owens RL. Influencing the decline of lung function in COPD: use of pharmacotherapy. Int J COPD. 2010;5:153\u201364.","journal-title":"Int J COPD"},{"issue":"6","key":"194_CR58","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1097\/CEJ.0b013e3282f75e48","volume":"17","author":"V Lemmens","year":"2008","unstructured":"Lemmens V, Oenema A, Knut IK, et al. Effectiveness of smoking cessation interventions among adults: a systematic review of reviews. Eur J Cancer Prev. 2008;17(6):535\u201344.","journal-title":"Eur J Cancer Prev"},{"key":"194_CR59","doi-asserted-by":"crossref","first-page":"17","DOI":"10.4137\/CCRPM.S7211","volume":"7","author":"S Ejiofor","year":"2013","unstructured":"Ejiofor S, Turner AM. Pharmacotherapies for COPD. Clin Med Insights Circ Respir Pulm Med. 2013;7:17\u201334.","journal-title":"Clin Med Insights Circ Respir Pulm Med"},{"key":"194_CR60","doi-asserted-by":"crossref","first-page":"179","DOI":"10.7326\/0003-4819-155-3-201108020-00008","volume":"155","author":"A Qaseem","year":"2011","unstructured":"Qaseem A, Wilt TJ, Weinberger SE, et al. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. Ann Intern Med. 2011;155:179\u201391.","journal-title":"Ann Intern Med"},{"key":"194_CR61","unstructured":"National Institute for Health and Clinical Excellence. CG101 Chronic obstructive pulmonary disease (updated): NICE guideline. http:\/\/guidance.nice.org.uk\/CG101\/NICEGuidance\/pdf\/English . Accessed 5 Dec 2013."},{"issue":"1","key":"194_CR62","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/MCP.0000000000000012","volume":"20","author":"D Spina","year":"2014","unstructured":"Spina D. Current and novel bronchodilators in respiratory disease. Curr Opin Pulm Med. 2014;20(1):73\u201386.","journal-title":"Curr Opin Pulm Med"},{"issue":"1","key":"194_CR63","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/1465-9921-14-49","volume":"14","author":"DP Tashkin","year":"2013","unstructured":"Tashkin DP, Ferguson GT. Combination bronchodilator therapy in the management of chronic obstructive pulmonary disease. Respir Res. 2013;14(1):49.","journal-title":"Respir Res"},{"issue":"4","key":"194_CR64","first-page":"409","volume":"1","author":"P Montuschi","year":"2006","unstructured":"Montuschi P. Pharmacological treatment of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2006;1(4):409\u201323.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"194_CR65","unstructured":"Boehringer Ingelheim. New once-daily Striverdi\u00ae (olodaterol) Respimat\u00ae gains approval in first EU countries [media release]. 18 Oct 2013. https:\/\/www.boehringer-ingelheim.com\/news\/news_releases\/press_releases\/2013\/18_october_2013_olodaterol.html ."},{"key":"194_CR66","unstructured":"GlaxoSmithKline plc, and Theravance Inc. RELVAR\u00ae ELLIPTA\u00ae receives European marketing authorisation for the treatment of asthma and COPD [media release]. 18 Nov 2013. http:\/\/www.gsk.com\/media\/press-releases\/2013\/relvar-ellipta-receives-european-marketing-authorisation-for-t.html ."},{"issue":"2","key":"194_CR67","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1016\/j.bmcl.2011.11.072","volume":"22","author":"JR Jacobsen","year":"2012","unstructured":"Jacobsen JR, Choi SK, Combs J, et al. A multivalent approach to the discovery of long-acting \u03b2(2)-adrenoceptor agonists for the treatment of asthma and COPD. Bioorg Med Chem Lett. 2012;22(2):1213\u20138.","journal-title":"Bioorg Med Chem Lett"},{"key":"194_CR68","first-page":"A653","volume":"177","author":"ED Bateman","year":"2008","unstructured":"Bateman ED, Make BJ, Nandeuil MA. Safety and tolerability of a long-acting beta2-agonist in patients with COPD [abstract]. Am J Respir Crit Care Med. 2008;177:A653.","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"194_CR69","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1124\/jpet.112.193284","volume":"342","author":"M Aparici","year":"2012","unstructured":"Aparici M, G\u00f3mez-Angelats M, Vilella D, et al. Pharmacological characterization of abediterol, a novel inhaled \u03b2(2)-adrenoceptor agonist with long duration of action and a favourable safety profile in preclinical models. J Pharmacol Exp Ther. 2012;342(2):497\u2013509.","journal-title":"J Pharmacol Exp Ther"},{"issue":"12","key":"194_CR70","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.2174\/0929867311320120003","volume":"20","author":"L Fuso","year":"2013","unstructured":"Fuso L, Mores N, Valente S, et al. Long-acting beta-agonists and their association with inhaled corticosteroids in COPD. Curr Med Chem. 2013;20(12):1477\u201395.","journal-title":"Curr Med Chem"},{"issue":"7\u20138","key":"194_CR71","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1345\/aph.1S002","volume":"47","author":"JA Woods","year":"2013","unstructured":"Woods JA, Nealy KL, Barrons RW. Aclidinium bromide: an alternative long-acting inhaled anticholinergic in the management of chronic obstructive pulmonary disease. Ann Pharmacother. 2013;47(7\u20138):1017\u201328.","journal-title":"Ann Pharmacother"},{"issue":"4","key":"194_CR72","doi-asserted-by":"crossref","first-page":"247","DOI":"10.2165\/00151829-200403040-00005","volume":"3","author":"SJ Keam","year":"2004","unstructured":"Keam SJ, Keating GM. Tiotropium bromide. A review of its use as maintenance therapy in patients with COPD. Treat Respir Med. 2004;3(4):247\u201368.","journal-title":"Treat Respir Med"},{"issue":"2","key":"194_CR73","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1124\/jpet.112.202051","volume":"345","author":"M Salmon","year":"2013","unstructured":"Salmon M, Luttmann MA, Foley JJ, et al. Pharmacological characterization of GSK573719 (umeclidinium): a novel, long-acting, inhaled antagonist of the muscarinic cholinergic receptors for treatment of pulmonary diseases. J Pharmacol Exp Ther. 2013;345(2):260\u201370.","journal-title":"J Pharmacol Exp Ther"},{"key":"194_CR74","unstructured":"GlaxoSmithKline plc. GSK announces regulatory submission for umeclidinium monotherapy in European Union [media release]. 26 Apr 2013. http:\/\/www.gsk.com\/media\/press-releases\/2013\/GSK-announces-egulatory-ubmission-or-meclidinium-onotherapy-in-european-union.html ."},{"key":"194_CR75","unstructured":"GlaxoSmithKline plc, and Theravance Inc. GSK and Theravance announce regulatory submission for ANORO\u2122 (UMEC\/VI) in Europe [media release]. 8 Jan 2013. http:\/\/www.gsk.com\/media\/press-releases\/2013\/gsk-and-theravance-announce-regulatory-submission-for-anoro-umec-vi-in-europe.html ."},{"key":"194_CR76","author":"DP Tashkin","year":"2013","unstructured":"Tashkin DP, Ferguson GT. Combination bronchodilator therapy in the management of chronic obstructive pulmonary disease. Respir Res. 2013. doi: 10.1186\/1465-9921-14-49 .","journal-title":"Respir Res"},{"issue":"1","key":"194_CR77","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.pupt.2012.07.003","volume":"26","author":"H Meurs","year":"2013","unstructured":"Meurs H, Dekkers BG, Maarsingh H, et al. Muscarinic receptors on airway mesenchymal cells: novel findings for an ancient target. Pulm Pharmacol Ther. 2013;26(1):145\u201355.","journal-title":"Pulm Pharmacol Ther"},{"key":"194_CR78","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1183\/09031936.00146610","volume":"38","author":"T Pera","year":"2011","unstructured":"Pera T, Zuidhof A, Valadas J, et al. Tiotropium inhibits pulmonary inflammation and remodelling in a guinea pig model of COPD. Eur Respir J. 2011;38:789\u201396.","journal-title":"Eur Respir J"},{"key":"194_CR79","doi-asserted-by":"crossref","unstructured":"Yu AP, Gu\u00e9rin A, Ponce de Leon D, et al. Therapy persistence and adherence in patients with chronic obstructive pulmonary disease: multiple versus single long-acting maintenance inhalers. J Med Econ. 2011;14(4):486\u201396.","DOI":"10.3111\/13696998.2011.594123"},{"issue":"3","key":"194_CR80","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.rmed.2010.09.006","volume":"105","author":"EL Toy","year":"2011","unstructured":"Toy EL, Beaulieu NU, McHale JM, et al. Treatment of COPD: relationships between daily dosing frequency, adherence, resource use, and costs. Respir Med. 2011;105(3):435\u201341.","journal-title":"Respir Med"},{"key":"194_CR81","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1183\/09031936.00168313","volume":"42","author":"N Roche","year":"2013","unstructured":"Roche N, Chanez P. Bronchodilator combinations for COPD: real hopes or a new Pandora\u2019s box? Eur Respir J. 2013;42:1441\u20135.","journal-title":"Eur Respir J"},{"issue":"7","key":"194_CR82","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1358\/dot.2013.49.7.1980496","volume":"49","author":"EN Schachter","year":"2013","unstructured":"Schachter EN. Indacaterol\/glycopyrronium bromide fixed-dose combination for the treatment of COPD. Drugs Today (Barc). 2013;49(7):437\u201346.","journal-title":"Drugs Today (Barc)"},{"key":"194_CR83","unstructured":"UK Medicines Information. New drugs online report for formoterol\u00a0+\u00a0glycopyrrolate. http:\/\/www.ukmi.nhs.uk\/applications\/ndo\/record_view_open.asp?newDrugID=5371 . Accessed 4 Dec 2013."},{"key":"194_CR84","unstructured":"Almirall, S.A. Aclidinium and formoterol fixed dose combination for COPD submitted for registration in Europe [media release]. 4 November 2013. http:\/\/investors.almirall.es\/phoenix.zhtml?c=209345&p=irol-newsArticle&ID=1871606&highlight=."},{"issue":"3","key":"194_CR85","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.pupt.2012.12.006","volume":"26","author":"M Cazzola","year":"2013","unstructured":"Cazzola M, Page C, Matera MG. Long-acting muscarinic receptor antagonists for the treatment of respiratory disease. Pulm Pharmacol Ther. 2013;26(3):307\u201317.","journal-title":"Pulm Pharmacol Ther"},{"issue":"3","key":"194_CR86","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/S2213-2600(13)70040-7","volume":"1","author":"MT Dransfield","year":"2013","unstructured":"Dransfield MT, Bourbeau J, Jones PW, et al. Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomized controlled trials. Lancet Respir Med. 2013;1(3):210\u201323.","journal-title":"Lancet Respir Med"},{"issue":"4","key":"194_CR87","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1345\/aph.1M243","volume":"44","author":"M-C Cyr","year":"2010","unstructured":"Cyr M-C, Beauchesne M-F, Lemi\u00e8re C, et al. Effects of inhaled corticosteroids in monotherapy or combined with long-acting \u03b22-agonists on mortality among patients with chronic obstructive pulmonary disease. Ann Pharmacother. 2010;44(4):613\u201322.","journal-title":"Ann Pharmacother"},{"key":"194_CR88","unstructured":"GlaxoSmithKline. Seretide Diskus 50\/100 microgram\/dose inhalation powder, predispensed: EU summary of product characteristics. 2007. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Referrals_document\/Seretide_Diskus_6_13\/WC500013534.pdf . Accessed 5 Dec 2013."},{"key":"194_CR89","unstructured":"Astra Zeneca UK Ltd. Symbicort\u00ae Turbohaler\u00ae 100 micrograms\/6 micrograms\/inhalation, inhalation powder: summary of product characteristics. 2013. http:\/\/www.medicines.org.uk\/emc\/medicine\/4820 . Accessed 5 Dec 2013."},{"key":"194_CR90","first-page":"73","volume":"7","author":"DP Tashkin","year":"2012","unstructured":"Tashkin DP, Doherty DE, Kerwin E, et al. Efficacy and safety characteristics of mometasone furoate\/formoterol fumarate fixed-dose combination in subjects with moderate to very severe COPD: findings from pooled analysis of two randomized, 52-week placebo-controlled trials. Int J COPD. 2012;7:73\u201386.","journal-title":"Int J COPD"},{"issue":"12","key":"194_CR91","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.2174\/0929867311320120003","volume":"20","author":"L Fuso","year":"2013","unstructured":"Fuso L, Mores N, Valente S, et al. Long-acting beta-agonists and their association with inhaled corticosteroids in COPD. Curr Med Chem. 2013;20(12):1477\u201395.","journal-title":"Curr Med Chem"},{"key":"194_CR92","doi-asserted-by":"crossref","unstructured":"Yang IA, Clarke MS, Sim EH, et al. Inhaled corticosteroids for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2012;7:CD002991.","DOI":"10.1002\/14651858.CD002991.pub3"},{"key":"194_CR93","doi-asserted-by":"crossref","unstructured":"Nannini LJ, Lasserson TJ, Poole P. Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2012;9:CD006829.","DOI":"10.1002\/14651858.CD006829.pub2"},{"issue":"Suppl 2","key":"194_CR94","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1586\/ers.13.14","volume":"7","author":"E Anton","year":"2013","unstructured":"Anton E. How and when to use inhaled corticosteroids in chronic obstructive pulmonary disease? Expert Rev Respir Med. 2013;7(Suppl 2):25\u201332.","journal-title":"Expert Rev Respir Med"},{"key":"194_CR95","author":"M Thomas","year":"2013","unstructured":"Thomas M, Radwan A, Stonham C, et al. COPD exacerbation frequency, pharmacotherapy and resource use: an observational study in UK primary care. COPD. 2013. doi: 10.3109\/15412555.2013.841671 .","journal-title":"COPD"},{"key":"194_CR96","unstructured":"Novartis. Novartis data presented at ERS showcases once-daily COPD portfolio and further demonstrates efficacy of Ultibro\u00ae Breezhaler\u00ae (QVA149) [media release]. 8 Sep 2013. http:\/\/www.novartis.com\/newsroom\/media-releases\/en\/2013\/1727858.shtml ."},{"issue":"5","key":"194_CR97","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1378\/chest.07-1167","volume":"133","author":"GJ Rodrigo","year":"2008","unstructured":"Rodrigo GJ, Nannini LJ, Rodriguez-Roisin R. Safety of long-acting beta-agonists in stable COPD: a systematic review. Chest. 2008;133(5):1079\u201387.","journal-title":"Chest"},{"key":"194_CR98","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1056\/NEJMoa1303342","volume":"369","author":"RA Wise","year":"2013","unstructured":"Wise RA, Anzueto A, Cotton D, et al. Tiotropium Respimat inhaler and the risk of death in COPD. New Engl J Med. 2013;369:1491\u2013501.","journal-title":"New Engl J Med"},{"issue":"4","key":"194_CR99","doi-asserted-by":"crossref","first-page":"271","DOI":"10.2165\/11589270-000000000-00000","volume":"30","author":"Rutten-van M\u00f6lken MP","year":"2012","unstructured":"Rutten-van M\u00f6lken MP. Goossens M. Cost effectiveness of pharmacological maintenance treatment for chronic obstructive pulmonary disease: a review of the evidence and methodological issues. Pharmacoeconomics. 2012;30(4):271\u2013302.","journal-title":"Pharmacoeconomics"},{"key":"194_CR100","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1136\/thx.2007.089557","volume":"63","author":"M Najafzadeh","year":"2008","unstructured":"Najafzadeh M, Marra CA, Sadatsafavi M, et al. Cost effectiveness of therapy with combinations of long acting bronchodilators and inhaled steroids for treatment of COPD. Thorax. 2008;63:962\u20137.","journal-title":"Thorax"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-014-0194-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-014-0194-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-014-0194-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,8]],"date-time":"2019-08-08T05:46:07Z","timestamp":1565243167000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-014-0194-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3]]},"references-count":100,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,3]]}},"alternative-id":["194"],"URL":"https:\/\/doi.org\/10.1007\/s40265-014-0194-8","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,3]]}}}